GSK selects Wave Life Sciences siRNA candidate, triggering $12M payment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to GSK selects Wave Life Sciences siRNA candidate, triggering $12M payment

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

September 30, 2026 7:30 AM EDT

Candidate selected by GSK utilizes Waves best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing

CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSKs development pipeline. This program was developed using Waves proprietary SpiNA design GalNAc-siRNA.

The advancement of this... More